Comparative Pharmacology
Head-to-head clinical analysis: OMNIPEN AMPICILLIN versus POLYMOX.
Peer-Reviewed Evidence
Head-to-head clinical analysis: OMNIPEN AMPICILLIN versus POLYMOX.
OMNIPEN (AMPICILLIN) vs POLYMOX
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), inhibiting transpeptidation and peptidoglycan cross-linking.
Amoxicillin is a bactericidal antibiotic that inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs) and inhibiting transpeptidase activity, leading to cell lysis.
250-500 mg orally every 6 hours; 500 mg to 2 g intramuscularly or intravenously every 4-6 hours.
250-500 mg orally every 8 hours or 500-875 mg orally every 12 hours; maximum 4 g/day.
None Documented
None Documented
Terminal elimination half-life is approximately 1-1.5 hours in adults with normal renal function. In neonates, it may be prolonged to 2-4 hours; in renal impairment, half-life can extend significantly (up to 8-20 hours in severe impairment).
Terminal elimination half-life = 1-1.5 hours in adults; prolonged in renal impairment (up to 12-20 hours in anuria)
Renal excretion accounts for approximately 90% of elimination, primarily via tubular secretion and glomerular filtration. Biliary/fecal excretion is minimal, <10%.
Renal (70-80% unchanged via tubular secretion and glomerular filtration); biliary/fecal (small amount, <5%)
Category A/B
Category C
Penicillin Antibiotic
Penicillin Antibiotic